Related Experiment Video
Updated: Apr 11, 2026
10:44
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
10.4K
CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects
Valentina Franco1, Emilio Perucca
1C. Mondino National Neurological Institute , Pavia , Italy.
Expert Opinion on Drug Metabolism & Toxicology
|June 4, 2015
Summary
Genetic variations in CYP2C9 significantly impact how the body processes phenytoin, an antiepileptic drug. Patients with specific CYP2C9 genotypes face higher risks of adverse effects from standard phenytoin doses.
Area of Science:
- Pharmacogenomics
- Drug Metabolism
- Clinical Pharmacology
Background:
- Phenytoin is an established antiepileptic drug with significant pharmacokinetic variability.
- Dosage individualization is crucial for optimizing phenytoin therapy.
- CYP2C9 is the primary enzyme responsible for phenytoin metabolism.
Purpose of the Study:
- To review the role of CYP2C9 genetic polymorphisms in phenytoin metabolism.
- To assess the impact of these polymorphisms on phenytoin clearance and adverse event susceptibility.
Main Methods:
- Comprehensive review of existing scientific literature.
- Critical analysis of evidence on CYP2C9 genetic variations and phenytoin pharmacokinetics.
- Evaluation of safety profiles associated with CYP2C9 genotypes.
Main Results:
- CYP2C9 genetic polymorphisms are a key factor influencing phenytoin metabolism rates.
- Other factors like CYP2C19, drug interactions, and physiological conditions also contribute.
- Patients with reduced CYP2C9 activity are at increased risk of central nervous system and severe cutaneous adverse reactions.
Conclusions:
- CYP2C9 genotype is a significant determinant of phenytoin metabolism and associated risks.
- The clinical utility and cost-effectiveness of CYP2C9 genotyping for phenytoin therapy require further investigation.
- Prospective studies are needed to validate the benefits of CYP2C9 genotyping in enhancing phenytoin treatment safety.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
125
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
125
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
218
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
218
01:27Pharmacogenetics of Drug Metabolism: Overview
148
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
148
01:25Pharmacokinetics: Drug–Drug Interactions
739
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
739
01:16Drug toxicity: Idiosyncratic Reactions
196
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
196
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
74
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
74